TCTR20180820002招募中2 期
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosis
Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital0 个研究点目标入组 15 人开始时间: 2018年8月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 N/A (No limit) 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •-patients with adenoma sebaceum
排除标准
- •-pregnancy
- •-allergic reaction to everolimus
研究者
相似试验
招募中
Unknown
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
已完成
2 期
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120
尚未招募
2 期
Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinomaon-clear cell renal cell carcinomaJPRN-UMIN000006248Yamaguchi University Graduate School of Medicine , Department of Urology10
进行中（未招募）
1 期
Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex.EUCTR2018-002531-18-FRHospices Civils de Lyon146
已完成
2 期
A phase 2 trial of EVERolimus alternating with SUNitinib as first line therapy for advanced renal cell carcinomaRenal Cell CarcinomaACTRN12609000643279The University of Sydney55